UBS Group’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $49.4M | Buy |
2,571,344
+166,640
| +7% | +$3.32M | 0.01% | 1656 |
|
|
2025
Q4 | $39.7M | Buy |
2,404,704
+392,351
| +19% | +$6.62M | 0.01% | 1872 |
|
|
2025
Q3 | $29.2M | Buy |
2,012,353
+1,061,589
| +112% | +$15.3M | ﹤0.01% | 2160 |
|
|
2025
Q2 | $13.3M | Buy |
950,764
+162,335
| +21% | +$2.28M | ﹤0.01% | 2804 |
|
|
2025
Q1 | $10.7M | Sell |
788,429
-64,432
| -8% | -$1.23M | ﹤0.01% | 2965 |
|
|
2024
Q4 | $17.4M | Buy |
852,861
+711,458
| +503% | +$18.2M | ﹤0.01% | 2477 |
|
|
2024
Q3 | $4.12M | Buy |
141,403
+5,180
| +4% | +$128K | ﹤0.01% | 3273 |
|
|
2024
Q2 | $3.16M | Sell |
136,223
-207,656
| -60% | -$3.99M | ﹤0.01% | 3297 |
|
|
2024
Q1 | $7.06M | Buy |
343,879
+52,894
| +18% | +$994K | ﹤0.01% | 2594 |
|
|
2023
Q4 | $6.24M | Buy |
290,985
+181,289
| +165% | +$3.59M | ﹤0.01% | 2535 |
|
|
2023
Q3 | $2.26M | Sell |
109,696
-22,244
| -17% | -$564K | ﹤0.01% | 3326 |
|
|
2023
Q2 | $3.89M | Buy |
131,940
+4,589
| +4% | +$129K | ﹤0.01% | 2830 |
|
|
2023
Q1 | $2.93M | Buy |
127,351
+7,170
| +6% | +$197K | ﹤0.01% | 3022 |
|
|
2022
Q4 | $3.34M | Buy |
120,181
+77,727
| +183% | +$2.31M | ﹤0.01% | 2872 |
|
|
2022
Q3 | $1.3M | Buy |
42,454
+36,079
| +566% | +$1.17M | ﹤0.01% | 3520 |
|
|
2022
Q2 | $188K | Sell |
6,375
-32,737
| -84% | -$858K | ﹤0.01% | 4973 |
|
|
2022
Q1 | $1.26M | Sell |
39,112
-53,236
| -58% | -$1.83M | ﹤0.01% | 3864 |
|
|
2021
Q4 | $4.12M | Buy |
92,348
+27,868
| +43% | +$1.32M | ﹤0.01% | 3037 |
|
|
2021
Q3 | $3.25M | Buy |
64,480
+62,043
| +2,546% | +$3.5M | ﹤0.01% | 3134 |
|
|
2021
Q2 | $191K | Sell |
2,437
-27,792
| -92% | -$1.72M | ﹤0.01% | 5382 |
|
|
2021
Q1 | $1.73M | Buy |
30,229
+24,433
| +422% | +$1.64M | ﹤0.01% | 3714 |
|
|
2020
Q4 | $485K | Sell |
5,796
-461
| -7% | -$27.9K | ﹤0.01% | 4620 |
|
|
2020
Q3 | $224K | Buy |
6,257
+3,570
| +133% | +$108K | ﹤0.01% | 4730 |
|
|
2020
Q2 | $65K | Sell |
2,687
-9,121
| -77% | -$214K | ﹤0.01% | 5651 |
|
|
2020
Q1 | $207K | Buy |
11,808
+9,500
| +412% | +$198K | ﹤0.01% | 4700 |
|
|
2019
Q4 | $40K | Sell |
2,308
-2,420
| -51% | -$40.3K | ﹤0.01% | 6476 |
|
|
2019
Q3 | $72K | Buy |
4,728
+459
| +11% | +$8.77K | ﹤0.01% | 5968 |
|
|
2019
Q2 | $89K | Buy |
4,269
+269
| +7% | +$6.03K | ﹤0.01% | 5451 |
|
|
2019
Q1 | $93K | Sell |
4,000
-74,485
| -95% | -$1.56M | ﹤0.01% | 5116 |
|
|
2018
Q4 | $1.62M | Buy |
78,485
+69,427
| +766% | +$1.26M | ﹤0.01% | 3239 |
|
|
2018
Q3 | $197K | Buy |
9,058
+14
| +0.2% | +$232 | ﹤0.01% | 5076 |
|
|
2018
Q2 | $138K | Sell |
9,044
-1,885
| -17% | -$35.5K | ﹤0.01% | 5214 |
|
|
2018
Q1 | $215K | Buy |
10,929
+10,729
| +5,365% | +$221K | ﹤0.01% | 4737 |
|
|
2017
Q4 | $3K | Buy |
+200
| New | +$3.59K | ﹤0.01% | 7526 |
|
Other funds holding DNLI
VCM
VPM
UBS Group's DNLI Position: Q1 2026 in Review
UBS Group increased its Denali Therapeutics (DNLI) stake by 6.9% in Q1 2026, buying an estimated $3.32M and bringing the position to 2,571,344 shares worth $49.4M. The position accounts for 0.01% of the portfolio, ranked #1656.
UBS Group first reported a position in DNLI in Q4 2017 and has held it in 34 quarters since. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- UBS Group held 2,571,344 shares of Denali Therapeutics worth $49.4M as of Q1 2026.
- UBS Group bought 166,640 Denali Therapeutics shares in Q1 2026, an estimated $3.32M.
- Denali Therapeutics made up 0.01% of UBS Group's portfolio in Q1 2026, its #1656 holding.
- UBS Group first reported a position in Denali Therapeutics in Q4 2017 and has held it in 34 quarters since.
- 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.